What guidance did Treace Medical's management provide for the next earnings period?

What were the key takeaways from Treace Medical’s earnings call?

What is the revenue and EPS growth rate for Treace Medical year over year?

What is Treace Medical's gross profit margin?

Did Treace Medical beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Treace Medical next quarter?

What were the key takeaways from Treace Medical's earnings call?

What factors drove the changes in Treace Medical's revenue and profit?

- **2026 Revenue Outlook**: $200M-$212M (-6% to 0% YoY), with Q4 growth from new product launches and case volume acceleration.
- **Product Expansion**: 5 new systems cover 100% of bunion procedures; 25% of surgeons adopted new systems within 2 quarters.
- **Cash Burn Reduction**: Target 50% reduction to $13.6M in 2026, supported by $115M credit facility.
- **TAM Expansion**: $300M adjacencies (mid-foot fusion, MTP fusion) with 2026 product launches (SuperBite, Speed XM).
- **Profitability Improvement**: Adjusted EBITDA loss narrows to $4M-$6M in 2026, from $(3.9M) in 2025.

**【CEO Summary Section】**
- Treace Medical has transformed into a comprehensive bunion solutions company, launching 5 best-in-class systems for all bunion deformity categories.
- 2026 revenue guidance: $200M-$212M (-6% to 0% YoY), driven by product mix shifts and economic headwinds, with Q4 growth expected from new product launches (Lapiplasty Lightning, Speed XM) and case volume acceleration.
- 25% of surgeon base adopted new bunion systems within 2 quarters, Q4 case volume growth exceeded mid-single digits.
- 2026 strategy: penetrate existing surgeon base with new products, expand into high-ASP adjacencies (mid-foot fusion, MTP fusion), and reduce cash burn by 50% (from $27.3M in 2025 to ~$13.6M in 2026).

**【CFO Financial Commentary】**
- Q4 2025: Revenue $62.5M (-9% YoY), Gross Margin 80.6%, Net Loss $94M, Adjusted EBITDA $(3.9M) (64% improvement vs 2024).
- Full year 2025: Cash usage $27.3M (-46% YoY), ending with $48.4M cash.
- 2026 Outlook: Adjusted EBITDA loss $4M-$6M, 50% reduction in cash burn, supported by $115M credit facility.

**【Q&A Highlights】**
- **Market Dynamics**: 2025 bunion procedure volume decline due to economic softness; 2026 expects similar headwinds but optimistic on new product uptake.
- **Product Mix Impact**: Lower ASP products (MIS osteotomy) drove 2025 revenue decline; 2026Q3+ will lap mix shift, with higher ASP 2026 launches (SuperBite, Speed XM).
- **New Product Development**: SuperBite screws and Speed XM mid-foot plating (mid-2026 launch) target $300M TAM expansion.
- **Competitive Strategy**: Comprehensive portfolio enables 100% bunion procedure coverage, reducing reliance on Lapiplasty (25% of surgeon volume).
- **Cash Flow Initiatives**: Annualizing 2025 restructuring savings, reducing DTC marketing, and lower CapEx for instrumentation trays.

Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 revenue of $50.2 million, targeting $211-213 million full year (1-2% growth). 
- **New Product Adoption**: 3 new bunion correction systems achieved 20%+ surgeon adoption in Q3. 
- **Profitability Improvement**: Adjusted EBITDA loss narrowed 49% YoY to $2.6 million in Q3. 
- **Liquidity Strength**: $80.6 million cash on hand with scalable business model and 79.1% gross margin.

**【Management Opening Remarks】**
- CEO John Treace highlighted a 11% year-over-year revenue growth in Q3 2025, driven by new bunion correction systems. The company expects to capture 20% of surgeon customers within one quarter of launch. 
- CFO Mark Hair reported a 79.1% gross margin and $50.2 million in Q3 revenue, with a focus on minimally invasive foot surgery (MIS) and bunion correction systems. 

**【CEO Commentary】**
- Launched 3 new bunion correction systems targeting $211-213 million full year 2025 revenue guidance (1-2% growth). 
- Q3 case volume growth of mid-single digits despite 7% decline in bunion procedure volumes among commercial insurers. 
- Investing $3 million in new product development for MIS foot surgery, with 20%+ surgeon adoption in Q3. 

**【CFO Financial Commentary】**
- Q3 2025 adjusted EBITDA loss of $2.6 million (49% improvement vs. Q3 2024). 
- Full year 2025 cash usage expected to decrease 17-58% YoY. 
- $80.6 million liquidity as of Q3 end, with scalable business model and 79.1% gross margin. 

**【Q&A Highlights】**
- 2026 outlook: >20% of surgeon customers expected to adopt new MIS foot surgery systems. 
- Restructuring initiatives to reduce operating expenses by 8% YoY. 
- 3 new bunion correction systems with >20% surgeon adoption in Q3. 
- 2025 full year revenue guidance of $211-213 million (1-2% growth).

Treace Medical Concepts, Inc. (TMCI) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 7% YoY to $47.4 million, with 2025 guidance of 7-10% growth ($224-230 million).
- **New Product Momentum**: 3 new systems targeting 70% of existing surgeon volumes, with Lapiplasty Lightning launching Q4 for 2026 acceleration.
- **Financial Improvement**: Adjusted EBITDA loss down 58% YoY to $3.6 million; cash usage reduced 55% QoQ.
- **Strategic Events**: September 3 Investor Day to highlight expanded portfolio and clinical evidence.

**【CEO Summary Section】**
- Q2 2025 revenue of $47.4 million, up 7% YoY, driven by expanded bunion solutions portfolio.
- Launched 3 new systems (Nanoplasty, Percuplasty, SpeedMTP) targeting 70% of existing surgeon volumes not previously addressed.
- 2025 full-year revenue guidance reaffirmed at $224-230 million (7-10% growth), with accelerating Q3 and Q4 growth.
- Introduced Lapiplasty Lightning system for limited market access in Q4, positioning for 2026 penetration acceleration.
- 3,100+ active surgeon customers (30% of U.S. bunion surgeons), with 30% penetration of their total bunion volumes.
- Clinical evidence milestone: 4-year ALIGN3D Lapiplasty study published, reinforcing market differentiation.

**【CFO Financial Commentary】**
- Q2 2025 financial highlights:
  - Revenue: $47.4 million (+7% YoY)
  - Gross margin: 79.7% (down 0.5% YoY)
  - Operating expenses: $54.7 million (-4% YoY)
  - Net loss: $17.4 million (-18% YoY)
  - Adjusted EBITDA loss: $3.6 million (58% improvement YoY)
  - Cash: $69.3 million (down $6.8 million QoQ)
- Full-year 2025 targets:
  - Revenue: $224-230 million
  - Adjusted EBITDA breakeven
  - Cash usage reduction of ~50% YoY

**【Q&A Key Highlights】**
- **New Product Adoption**: Surgeons using new systems are also adopting core Lapiplasty technology, with Q3/Q4 inventory sufficient to meet demand.
- **Market Trends**: Q2 procedure delays pushed to Q4, aligning with seasonal trends; no lost cases expected.
- **2026 Outlook**: Lapiplasty Lightning system positioned to drive double-digit growth, complemented by expanding commercial team.
- **Inorganic Growth**: Open to tuck-in acquisitions to complement organic portfolio expansion.
- **Investor Day**: September 3 event to showcase expanded portfolio and clinical evidence.

Treace Medical Concepts, Inc. (TMCI) Q2 2025 Earnings Call Transcript

- **Q1 2025 Strong Start**: $52.6M revenue (+4.5% adj.), setting stage for 7-10% YoY growth
- **New Product Expansion**: 3 new systems to target 75% of surgeons' cases not served by Lapiplasty
- **Profitability Progress**: Adjusted EBITDA loss -54% YoY, on track for 2025 breakeven
- **Back-Half Growth**: Q3 launches + seasonal demand to drive 4Q acceleration
- **Minimal Cannibalization**: New osteotomy systems address surgeons preferring non-Lapiplasty approaches

**【CEO Summary Section】**
- Q1 2025 revenue: $52.6 million (+3% YoY, +4.5% adj. for 1 less selling day)
- New product launches (Nanoplasty, Percuplasty, SpeedMTP) targeting 75% of surgeons' cases not served by Lapiplasty
- 2025 revenue guidance: $224-230 million (7-10% YoY growth)
- Back-half growth driven by Q3 product launches and seasonal demand
- Lapiplasty Lightning system to be released late 2025

**【CFO Financial Commentary】**
- Q1 2025 financials:
  - Gross margin: 79.7% (vs. 80.2% YoY)
  - Operating expenses: $57.5 million (-4% YoY)
  - Net loss: $15.9 million (-15% YoY)
  - Adjusted EBITDA loss: $3.8 million (54% improvement YoY)
  - Cash: $76.1 million (stable vs. Q4 2024)
- Full-year 2025 targets:
  - Breakeven adjusted EBITDA
  - 50% reduction in cash burn vs. 2024

**【Q&A Key Takeaways】**
1. **Competitive Positioning**: 
   - Lapiplasty remains market leader with 25% share of surgeons' cases
   - New osteotomy systems target multiline competitors' weaknesses
   - Training labs oversold, indicating strong surgeon interest

2. **Product Cannibalization**: 
   - Minimal risk; new systems address surgeons preferring osteotomies
   - Lapiplasty growth expected to remain low-mid single digits
   - New products to drive back-half acceleration

3. **Revenue Timing**: 
   - Q2 2025 growth ~6% (similar to Q2 2024)
   - 1% of annual revenue shifted from Q2 to Q4 due to deductible timing
   - Full-year guide unchanged at $224-230 million

4. **Cost Management**: 
   - 3 consecutive quarters of EBITDA improvement
   - R&D investments balanced with expense control
   - 50% cash burn reduction target on track

Treace Medical Concepts (TMCI)-8 May 25-2025 Q1 Earnings call transcript

- **Revenue Momentum**: Q4 2024 up 10.4% YoY to $68.7M, with 2025 guidance of $224-230M (7-10% growth). New products (Nanoplasty, Percuplasty) to drive H2 2025 growth.
- **Portfolio Expansion**: 4 new technologies targeting all 4 bunion classes, with 3,100+ surgeons ready to adopt. SpeedPlate adoption >50% of fixation mix.
- **Profitability Turnaround**: 2025 breakeven adjusted EBITDA, 50% reduction in cash burn, fueled by sales force leverage and cost efficiency.
- **Market Leadership**: Lapiplasty maintains U.S. dollar share leadership; new products aim to capture 75% of untapped surgeon procedures.


**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 revenue reached $68.7 million, up 10.4% YoY, driven by new product adoption (e.g., Adductoplasty, SpeedPlate) and expanded surgeon base (3,100+ active users). Full-year 2024 revenue was $209.4 million, a 12% increase.
- **Product Portfolio Expansion**: Introduced 4 new technologies targeting all 4 bunion classes: Nanoplasty (3D MIS osteotomy), Percuplasty (instrumented MIS osteotomy), SpeedMTP (MTP fusion), and Mini-Adductoplasty. These are expected to ramp in H2 2025.
- **2025 Guidance**: Revenue of $224-230 million (7-10% growth), breakeven adjusted EBITDA, and reduced cash burn by 50% YoY.
- **Market Position**: Lapiplasty remains the U.S. dollar share leader, with 25% penetration of surgeons' procedures. New products aim to capture the remaining 75% of cases.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: GAAP net loss of $0.5 million (-$0.01 per share), compared to $6.3 million (-$0.10) in Q4 2023. Adjusted EBITDA improved to $11.1 million (vs. $2.6 million YoY). Full-year 2024 adjusted EBITDA loss narrowed to $11 million (vs. $24.4 million YoY).
- **Gross Margin**: 80.7% in Q4 2024, down from 81.6% YoY, due to product mix shift. Full-year gross margin was 80.4% (vs. 81.2% YoY).
- **Cash Position**: $75.7 million as of Dec 31, 2024, with $26 million available via revolver. Full-year 2025 cash burn expected to decrease by 50%.

**【Q&A Highlights】**
- **Q1 2025 Outlook**: Toughest comp quarter, with low-single-digit growth, followed by accelerating growth in H2 2025.
- **Product Impact**: New osteotomy systems (Nanoplasty, Percuplasty) target mild-to-moderate bunions, complementing Lapiplasty's moderate-to-severe focus. SpeedPlate adoption exceeds 50% of fixation mix.
- **Competitive Dynamics**: No material impact from Zimmer Paragon deal; surgeons returning to Lapiplasty post-competitive trials.
- **Profitability**: 2025 breakeven EBITDA driven by sales force leverage (higher commission-based reps, reduced hiring) and cost control.


Actual	-0.0692	-0.1	-0.12	-0.12	-0.16	-0.2305	-0.22	-0.08	-0.23	-0.2	-0.28	-0.1	-0.3	-0.34	-0.25	-0.01	-0.25	-0.28	-0.26	-0.1503
Forecast	-0.08	-0.12	-0.1192	-0.0058	-0.2025	-0.2064	-0.2865	-0.1394	-0.2288	-0.241	-0.2642	-0.0883	-0.302	-0.2908	-0.2717	-0.0385	-0.3019	-0.2884	-0.2756	-0.1543
Surprise	+13.50%	+16.67%	-0.67%	-1968.97%	+20.99%	-11.68%	+23.21%	+42.61%	-0.52%	+17.01%	-5.98%	-13.25%	+0.66%	-16.92%	+7.99%	+74.03%	+17.19%	+2.91%	+5.66%	+2.59%

TMCI

TMCI fundamentals

TMCI Q4 2025 Earnings

Earnings Call

You can ask Aime

TMCI

TMCI fundamentals

TMCI Q4 2025 Earnings

Earnings Call

TMCI Earnings Call Summary for Q4/20258:00 AM on Feb 27, 2026

TMCI Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

TMCI Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

TMCI Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

TMCI Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

You can ask Aime